News

Hookipa Appoints Dr. Christoph Lengauer to its Board of Directors as a...

Dr. Lengauer has an outstanding track-record in cancer drug discovery,...

Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop...

Hookipa and Gilead will jointly develop therapeutics against HIV and Hepatitis...

New Insights into Hookipa’s TheraT® Replicating Viral Vector Platform...

TheraT®-induced CD8+ T cells are resistant to select checkpoint inhibitors,...

Hookipa Biotech to Present New Phase 1 Data for its Cytomegalovirus Vaccine,...

Vaccine has a good safety profile and elicits strong humoral and cellular...

Hookipa Biotech To Present at the Cowen and Company 38th Annual Healthcare...

The presentation will be held by Joern Aldag, CEO of Hookipa Biotech. He will...

Hookipa Biotech to Attend the LEERINK Partners 7th Annual Global Healthcare...

Mr. Aldag and Dr. Matushansky will participate in a series of one-on-one...

Hookipa Biotech to Present at 36th Annual J.P. Morgan Healthcare Conference...

Mr. Aldag will provide an overview of the Company´s strategy as well as an...

Hookipa Biotech Raises $60 million (€50 million) in an Oversubscribed Round C...

The round was led by an undisclosed blue chip U.S. public investment fund...

Dr. Jan van de Winkel Joins Hookipa as Chairman of its Board of Directors

Dr. Jan van de Winkel is currently President and Chief Executive Officer of...

Hookipa Biotech Announces Nature Communications Publication Showing TheraT®...

“This key research data is the first publication on Hookipa’s platform...

Hookipa Biotech presents positive data from Phase 1 first-in-human trial of...

Vaccine was safe and elicited a potent immune response. Cytomegalovirus (CMV)...

Reinhard Kandera Appointed Chief Financial Officer of Hookipa Biotech

Reinhard Kandera has more than 20 years of professional experience in the...

Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa...

Dr. Matushansky joins Hookipa from Daiichi Sankyo, where he was the Global...

Hookipa Biotech Announces Publication in Clinical and Vaccine Immunology...

Cytomegalovirus (CMV) infection is the leading cause of congenital infection...

Hookipa Secures EUR 4.16 million Additional Grant Support from the Austrian...

A EUR 4.16 million grant has been awarded for the second year of a multi-year...

Dr. Torsten Mummenbrauer Appointed SVP Business Development & Licensing of...

Dr. Mummenbrauer brings almost 20 years of business development experience in...

Hookipa Biotech Initiates First-in-Human Study of Cytomegalovirus Vaccine

HB-101 is a bivalent vaccine containing two recombinant, replication-deficient...

Jörn Aldag Appointed CEO of Hookipa Biotech

Vienna, Austria, 16 June 2016 - Hookipa Biotech AG, a company pioneering a new...